Results 251 to 260 of about 16,748,637 (363)

Elevated Salivary Theobromine and Long‐Term Improvement of Periodontal Health in Two Cohort Studies

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Background Theobromine, a methylxanthine mainly found in chocolate, has been suggested to possess various health‐promoting properties. This study aimed to investigate the long‐term effect of salivary theobromine levels on periodontitis severity using 7‐ and 10‐year follow‐up data from the prospective Studies of Health in Pomerania (SHIP‐TREND ...
Thomas Kocher   +8 more
wiley   +1 more source

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp   +5 more
wiley   +1 more source

Meiotic Arrest In Vitro by Phosphodiesterase 3-Inhibitor Enhances Maturation Capacity of Human Oocytes and Allows Subsequent Embryonic Development1

open access: yesBiology of Reproduction, 2006
D. Nogueira   +6 more
semanticscholar   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui   +15 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

Role of Phosphodiesterase 3 in NO/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells

open access: yesCirculation Research, 2003
T. Aizawa   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy